1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6395253244DD37C6400258AF60025B803
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-establishing-apac-standards-field-medical-performance-excellence?opendocument
18
19opendocument
2034.236.191.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Establishing APAC Standards for Field Medical Performance Excellence

ID: 5801


Features:

10 Info Graphics

30 Data Graphics

480+ Metrics

12 Narratives


Pages/Slides: 46


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Establishing APAC Standards for Field Medical Performance Excellence”

STUDY OVERVIEW

The Asia-Pacific region presents distinct challenges and opportunities for field medical teams due to its varied regulatory, cultural, and healthcare environments. Despite challenges, the region's high demand for new treatments offers significant growth potential, necessitating adaptive approaches from field medical teams to engage key stakeholders effectively.

This benchmarking study was conducted by Best Practices, LLC to provide invaluable insights to field medical leaders, empowering them to overcome challenges and seize opportunities in the APAC region. By delving into key insights and benchmarks, our study offers a roadmap for optimizing field medical operations across the Asia-Pacific region.

Leveraging a robust dataset,
the research additionally provides segmented insights at the country level, offering valuable benchmarks for the Australia, China, and Japan markets.

KEY TOPICS

  • Effective Field Performance Metrics in the APAC Region
  • Framework for Field Medical Excellence
  • KOL Targeting and Engagement Levels in the APAC Region
  • Average MSL Time Allocation for KOL Interactions and Internal Activities
  • APAC Field Medical Staffing Footprint
  • Key Lessons Learned for Measuring MSL Impact in the APAC Region

KEY METRICS

  • Average total panel size supported by an individual MSL across APAC, including separate figures for Australia, China, and Japan
  • Average number of monthly KOL/HCP and F2F meetings in APAC, with specific data for Australia, China, and Japan
  • Average time spent in KOL interactions in APAC, along with separate figures for Australia, China, and Japan
  • Value assigned to each interaction type on the MSL scorecard across APAC, with individual breakdowns for Australia, China, and Japan
  • Optimal and widely utilized field metrics for assessing and showcasing MSL impact across the APAC region
  • Engagement metrics for non-tiered KOLs in APAC, covering Australia, China, and Japan, with separate metrics for each country
  • Average annual field presence of MSLs across APAC, including separate figures for Australia, China, and Japan
  • Time spent by MSLs on external, internal, and logistics activities in APAC, with separate breakdowns for Australia, China, and Japan
  • Weekly MSL time allocation across activity streams in APAC, with specific data for Australia, China, and Japan
  • MSL engagement mix across APAC, including separate breakdowns for Australia, China, and Japan
  • Field medical staffing footprint across APAC, with separate figures provided for Australia, China, and Japan
  • Span of control: Number of MSLs per MSL manager across APAC, with separate data for Australia, China, and Japan

SAMPLE KEY FINDINGS

  • Average Time in KOL Interactions: The average duration of KOL interactions in the Asia-Pacific region is 30 minutes, compared to 2022 average of 35 minutes, reflecting a slight decrease in interaction time.

METHODOLOGY

This study offers tailored benchmarks and insights focused on the Asia-Pacific region. The data from this study is drawn from a larger global pool of field leaders, featuring 448 survey responses from over 100 biopharma manufacturers across the world. The data is meticulously segmented at both regional and country levels to offer nuanced insights.


Additionally, Best Practices, LLC utilizes its proprietary Field Medical Excellence database to provide additional benchmarks tailored to align with varied portfolio considerations.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.